Biotest AG: Successful start into the Year 2008
Biotest AG / Quarter Results
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest AG: Successful Start into 2008
- Q1 Sales of EUR 105.5 million: 39% higher than in the same period of
last year
- Operating profit (EBIT) increased to EUR 13.3 million compared to
EUR 8 million in Q1 2007
Dreieich, 16 May 2008. Financial year 2008 started well for Biotest Group.
In the first quarter, the company, which specialises in pharmaceuticals,
biotherapeutics and diagnostics, recorded sales totaling EUR 105.5 million.
That represents an increase of 39.4% compared with the first three months
in 2007 (EUR 75.7 million). Even without the sales of EUR 16.2 million of
Biotest's new US pharma subsidiary, Biotest Pharmaceuticals Corp. (BPC),
the sales of the Group in last year's structure are 18% higher than in the
first quarter of 2007.
Earnings before interest and taxes (EBIT) were up to EUR 13.3 million
compared to EUR 8.0 million in the same period 2007. Without the EBIT
contribution of BPC ( EUR 1.7 million) that is still an increase by 45%
compared to the first quarter in 2007.
More details on sales and earnings of the four segments Plasmaproteins,
Biotherapeutica, Immunology and Mikrobiology are given in Biotest's
Quarterly Report as of 31 March 2008. The Quarterly Report can be seen and
downloaded on Biotest's homepage (www.biotest.com).
The Management Board of Biotest will give a detailed overview of the
business development of the last year and the last quarter as well as of
the ongoing and planned projects at the Annual Shareholders' Meeting on
Tuesday, May 27th 2008. The Annual Shareholders' Meeting will take place at
the Congress Center Messe Frankfurt in Frankfurt and will start at 10:30
a.m.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,800
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard and S-DAX.
Biotest AG:
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth
Tel: +49 (0) 6103 801-338
Fax: +49 (0) 6103 801-347
e-mail: michael_ramroth@biotest.de
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
16.05.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-8 80
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
